Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ. Bajrami I, et al. Among authors: natrajan r. Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603. Cancer Discov. 2018. PMID: 29610289 Free PMC article.
Resistance to therapy caused by intragenic deletion in BRCA2.
Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Edwards SL, et al. Among authors: natrajan r. Nature. 2008 Feb 28;451(7182):1111-5. doi: 10.1038/nature06548. Epub 2008 Feb 10. Nature. 2008. PMID: 18264088
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS. Arriola E, et al. Among authors: natrajan r. Lab Invest. 2008 May;88(5):491-503. doi: 10.1038/labinvest.2008.19. Epub 2008 Mar 10. Lab Invest. 2008. PMID: 18332872 Free article.
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS. Tan DS, et al. Among authors: natrajan r. Clin Cancer Res. 2009 Apr 1;15(7):2269-80. doi: 10.1158/1078-0432.CCR-08-2403. Epub 2009 Mar 17. Clin Cancer Res. 2009. PMID: 19293255
Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
Natrajan R, Lambros MB, Rodríguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchió C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, Hungermann D, Mackay A, Grigoriadis A, Fenwick K, Tamber N, Hardisson D, Tutt A, Palacios J, Lord CJ, Buerger H, Ashworth A, Reis-Filho JS. Natrajan R, et al. Clin Cancer Res. 2009 Apr 15;15(8):2711-22. doi: 10.1158/1078-0432.CCR-08-1878. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318498 Free article.
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS. Natrajan R, et al. Breast Cancer Res Treat. 2010 Jun;121(3):575-89. doi: 10.1007/s10549-009-0501-3. Epub 2009 Aug 18. Breast Cancer Res Treat. 2010. PMID: 19688261
133 results